Your session is about to expire
← Back to Search
Atorvastatin for Cancer
Study Summary
This trial will test if atorvastatin can decrease the level of mutant p53 in cancer patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 3 trial • 58 Patients • NCT02084069Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I had cancer before, but it's been in complete remission for over 2 years and I don't need treatment now.I have been diagnosed with squamous cell cancer of the oropharynx.I have taken statins in the last 30 days.I do not drink more than 4 (if male) or 2 (if female) alcoholic drinks a day.I have had rhabdomyolysis in the past.I have an ongoing liver condition.I am currently taking medication that can cause muscle weakness.My thyroid condition has not been treated.I understand the study and can sign the consent myself.My tumor is positive for the TP53 protein.My cancer does not show TP53 protein in the screening.I have AML and am between treatments after a relapse.I haven't had any cancer treatments like chemotherapy or immunotherapy in the last 30 days.My cancer tissue samples are suitable for detailed genetic testing.My organs and bone marrow are working well.I agree to use two forms of birth control or practice abstinence during and 90 days after the study.I am fully active or can carry out light work.I have a confirmed cancer diagnosis and am eligible for surgery to remove it.
- Group 1: Atorvastatin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the government sanctioned Atorvastatin for medicinal use?
"Due to the fact that Atorvastatin is in Phase 1 trials, our team at Power assigned it a score of 1 out of 3 on safety considerations. This indicates limited evidence supporting its efficacy and safety."
How many participants is the trial enrolling?
"That is accurate. On clinicaltrials.gov, the information discloses that this study has opened recruitment and requires 50 participants from a single medical centre. This trial was first published on July 19th 2018 and its details were last updated on May 18th 2022."
Is this research program still looking for participants?
"According to clinicaltrials.gov, this experiment is currently in its recruitment stage. It was initially posted on July 19th 2018 and the information has been refreshed as recently as May 18th 2022."
What medical conditions have been seen to benefit from Atorvastatin?
"Atorvastatin is a common remedy for treating lipidemias, as well as postoperative thromboembolism, anginal pain, and transient ischemic attack."
Is this particular medical experimentation unprecedented?
"Since its initiation in 2005, Atorvastatin has been the subject of numerous studies sponsored by Merck Sharp & Dohme LLC. After 80 patients were observed under Phase 1 trials, this medication was approved for use and is now studied at 70 different locations spanning 28 countries."
Share this study with friends
Copy Link
Messenger